Loan Loss Reserves / Non-Performing Loans (Quarterly)

Loan Loss Reserves / Non-Performing Loans: Allowance for bad loans as a portion of total loans made. Calculated as: Loan Loss Reserves / Non-Performing Loans

Apellis Pharmaceuticals, Inc. (APLS) Loan Loss Reserves / Non-Performing Loans data is not available.

Quarterly Annual

Figures for fiscal quarter ending 2025-03-31

Income Statement Financials
Revenue	$166.80M
Net Income	$-92.22M
Cost of Goods Sold	$34.36M
Gross Profit	$132.44M
Operating Expenses	$250.12M
Operating Income	$-83.33M
Non-Operating Income/Expense	$-8.56M
Pre-Tax Income	$-91.88M
Normalized Pre-Tax Income	$-91.88M
Income after Taxes	$-92.22M
Income from Continuous Operations	$-92.22M
Consolidated Net Income/Loss	$-92.22M
Normalized Income after Taxes	$-92.22M
EBIT	$-83.33M
EBITDA	$-82.29M
Weighted-Average Shares Outstanding (Basic)	125.45M
Weighted-Average Shares Outstanding (Diluted)	125.45M
Earnings per Share (EPS) (Basic)	$-0.74
Earnings per Share (EPS) (Diluted)	$-0.74
Balance Sheet Financials
Current Assets	$727.72M
Property, Plant, and Equipment	$2.51M
Long-Term Assets	$79.57M
Total Assets	$807.28M
Current Liabilities	$178.38M
Long-Term Debt	$453.42M
Long-Term Liabilities	$464.69M
Total Liabilities	$643.07M
Common Equity	$164.22M
Tangible Shareholders Equity	$164.22M
Shareholders Equity	$164.22M
Common Shares Outstanding	125.66M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-53.41M
Cash Flow from Investing Activities	$-0.01M
Cash Flow from Financial Activities	$0.27M
Beginning Cash	$412.61M
End Cash	$359.83M
Increase/Decrease in Cash	$-52.78M
Stock-Based Compensation	$27.37M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	4.08
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.73
Debt to Equity Ratio	2.76
Gross Margin	79.40%
Operating Margin	-49.96%
EBIT Margin	-49.96%
EBITDA Margin	--
Pre-Tax Profit Margin	-55.09%
Profit Margin	-55.29%
Free Cash Flow	$-53.42M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.21
Inventory Turnover	0.42
Receiveable Turnover	0.71
Days Sales in Receivables	126.93
Return on Equity	-56.16%
Return on Tangible Equity	-56.16%
Return on Assets	-11.42%
Return on Investments	-14.93%
Book Value Per Share	$1.31
Free Cash Flow per Share	$-0.43
Operating Cash Flow per Share	$-0.43

Data from Zacks Investment Research, Inc.